Effect of Dapagliflozin on Albuminuria and HbA1c in Diabetic Patients in Dubai: A Real-World Study

Background: Albuminuria and poor glycemic control drive kidney and cardiovascular risk in type 2 diabetes. Dapagliflozin lowers glucose and reduces albuminuria through renal mechanisms. Evidence from trials is strong, yet data from routine care in Dubai are limited. Objective: To evaluate changes in urine albumin-to-creatinine ratio and HbA1c over 24 months after dapagliflozin initiation in Dubai primary care. Methods: We performed a retrospective longitudinal study using the Salama electronic record across Dubai Health Authority clinics. Adults with type 2 diabetes who started dapagliflozin contributed measurements at baseline, 3, 6, 12 and 24 months. The primary outcome was change in UACR. Secondary outcome was change in HbA1c. Paired comparisons used baseline vs each follow-up. Longitudinal trends used repeated measures analyses. Prespecified subgroups assessed UACR by age group and HbA1c by sex, age and metformin use. Results: Two hundred adults were included. Mean age was 61 years, range 21 to 87 years. UACR fell from 123 mg/g at baseline to 52 mg/g at 24 months, a 57.7% reduction, p